Virtus Investment Partners VRTS

$133.81 +1.03 (0.78%)

Valuation

Market cap
886,184,000
Revenue TTM
$852,870,000
Net income TTM
$138,400,000
PE ratio
5.51
Forward PE
5.79
Profit margin
16.23%
Debt to equity
0.44

Trading

Volume
117,800
Avg volume
135,908
Day's range
$132.06 – $135.99
Shares out
6,623,000
Stochastic %K
75%
Beta
1.41
Analysts
Hold
Price target
$145.50

Price

Company profile

Virtus Investment Partners, Inc. is a publicly owned investment manager. The firm primarily provides its services to individual and institutional clients. It launches separate client focused equity and fixed income portfolios. The firm launches equity, fixed income, and balanced mutual funds for its clients. It invests in the public equity, fixed income, and real estate markets. The firm also invests in exchange trad...

Show more

Virtus Investment Partners, Inc. is a publicly owned investment manager. The firm primarily provides its services to individual and institutional clients. It launches separate client focused equity and fixed income portfolios. The firm launches equity, fixed income, and balanced mutual funds for its clients. It invests in the public equity, fixed income, and real estate markets. The firm also invests in exchange traded funds. It employs a multi manager approach for its products. The firm employs quantitative analysis to make its investments. It benchmarks the performance of its portfolios against the S&P 500 Index. The firm conducts in-house research to make its investments. Virtus Investment Partners, Inc. was founded in 1995 and is based in Hartford, Connecticut.

Industry
Asset Management
Sector
Financial Services
Phone
800-248-7971
Website
https://corporate.virtus.com
Address
One Financial Plaza, Hartford, United States

Latest news

Stocktwits

macrossluvsrobotech Sep 1, 3:47 PM
$LXRX $NVO $VRTS $BIB $SPY
0 replies
macrossluvsrobotech Sep 1, 3:45 PM
$LXRX dip is the seller’s loss. First principles: Value ≈ P(approval) × payoff, and P just rose. STENO1 hit the FDA exposure bar in late August, showing DKA rates matching standard of care and well below inTandem—clearing the historical ~3.5 DKA/100 patient-years gating variable. Q4 NDA resubmission brings the first oral insulin adjunct for T1D glycemic control to ~1M US adults. Bayes prior: Administrations deliver high-salience, kitchen-table health wins into midterms (like the IRA $35 insulin cap in Aug '22). Amid soft jobs and sticky inflation, a non-injectable T1D option is prime political currency. Sellers just handed shares over while the clock runs toward filing. N/FA. Zynquista refiling overview This short video provides a quick overview of Lexicon's regulatory timeline and plans for refiling Zynquista in type 1 diabetes. $NVO $BIB $VRTS https://youtu.be/NPGAZFACUoc?si=N7pwImDrGAxveMWM
0 replies
macrossluvsrobotech Aug 31, 4:56 PM
$LXRX $NVO $VRTS $BIB $LLY $LXRX Viral "China cured diabetes" posts mash TWO separate, early-stage trials into a fake national rollout 'news'. 1️⃣ 2024 Cell Study: Only 1 patient, who was already on heavy anti-rejection drugs from a prior liver transplant. 2️⃣ 2026 Lancet Study (E-islet01): Just 3 patients. Mixed results, requires lifelong immunosuppression, and costs $150K+ per custom surgery with no retail price or approval. REALITY: Boutique experimental surgeries are years away from mass scale. They are NOT products you can buy today. WHY IT MATTERS FOR $LXRX: Complex cell procedures with lifelong drug risks can’t help millions right now. That's why accessible, daily oral treatments like Zynquista remain the urgent, scalable winner for Type 1 Diabetes! 📈 NFA Youtube video From Chinese News Service: CNS : https://youtu.be/FdGvAK9qSf0?si=19AM01nKREMtalp5
0 replies
macrossluvsrobotech Aug 31, 4:42 PM
$LXRX viral “China cured diabetes” posts mash TWO studies. Not a product. 2024 Cell (Deng/Tianjin): ONE published T1D woman. Off insulin day 75. Already on liver-transplant immuno. 1-year paper. Not this weekend. https://www.cell.com/cell/fulltext/S0092-8674(24)01022-5 2026 Lancet (E-islet01, Shanghai): THREE T1D cases. Pt1 first graft FAILED. Redo + heavy immuno: 54→8 units, not off. Pt2 off insulin >26 mo. Pt3 56→16 units, not off. Needs immuno. No list price. China/US IND only. Not approved. https://www.thelancet.com/journals/landia/article/PIIS2213-8587(25)00423-1/fulltext Boutique transplant ≠ 2026 pill. Does not move Zynquista Q4 2026 file. $NVO $VRTS $BIB $LLY
0 replies
macrossluvsrobotech Aug 31, 3:49 PM
$LXRX :Why Low-BP Matters 🫀 BP (Blood Pressure) is the force of blood against artery walls (Systolic top number over Diastolic bottom). SBP is Systolic Blood Pressure (the top number when the heart beats). Normally, doctors fear treating fragile heart failure patients with SBP < 110 ( lower than 110) (top number under 110 mmHg) because meds can crash BP ( Blood Pressure ) or cause kidney stress. Lexicon's new trial data solves this. Sotagliflozin achieved an HR 0.56 (Hazard Ratio), meaning patients on the drug had 56% of the adverse events of placebo ( ALMOST HALF!!), vs 100% , 100 minus 56 = a 44% reduction in CV (Cardiovascular)-death/HF ( Heart Failure) events. Physically, it unloads heart fluid via dual SGLT1/2 inhibition without crashing BP or causing kidney injury (zero difference vs placebo). The point: INPEFA is safe and effective when BP ( Blood Pressure) is low! $NVO $VRTS $BIB $LLY
0 replies
macrossluvsrobotech Aug 31, 3:29 PM
$LXRX Cardio Landscape NEWS TODAY in Plain English! 🫀📊 $LLY latest Cardio News Today , how it affects $LXRX Cardio treatment: 1. LLY MOUNJARO: FDA approved to cut MACE (heart attacks/strokes). Trial was vs Trulicity ($LLY's older GLP-1) showing HR 0.92 (8% risk cut). Mounjaro targets plaque; INPEFA clears fluid in heart failure. They don't compete—doctors use both! $CYTK recent news, how it affects $LXRX 2. CYTK SAFETY FLAW: Aficamten (myosin inhibitor) turns down heart squeeze. Symptom gains were tiny (KCCQ +3.0), but 10.5% suffered a dangerous heart pump drop (LVEF <50% vs 0.8% placebo). Pump tax! $LXRX’s SONATA-HCM treats stiff hearts WITHOUT weakening the pump. 3. LXRX NEW DATA TODAY: Analyzed low blood pressure patients (top number SBP <110). Sotagliflozin delivered HR 0.56 = 44% reduction in CV death & HF events (p=0.03) with ZERO excess kidney damage or fainting vs placebo. Proves safety in fragile patients! $NVO $VRTS PR: https://lexiconpharma.gcs-web.com/news-releases/news-release-details/lexicon-announces-new-post-hoc-soloist-whf-analysis
0 replies
macrossluvsrobotech Aug 28, 2:21 PM
$LXRX LXRX THEY ARE SELLING YOU BOTH ALPHA AND AN INFLATION HEDGE, WAR HEDGE, OIL HEDGE AT A FIRESALE PRICE, BECAUSE THEY CAN'T TAKE THE TIME TO READ THE HCM RESULTS, FROM $CYTK . $CYTK = HCM ( A COMPLETELY DIFFERENT CHEMICAL PATHWAY THAN SOTAGLIFLOZIN) PHASE 3 RESULTS ( TELLS THE HEART TO SLOW DOWN, DUE TO INFLEXIBLE HEART MUSCLE WALL, BRINGING HEART DANGEROUSLY CLOSE TO STOPPING ALL TOGETHER) = BAD VS $LXRX = HCM ( A COMPLETELY DIFFERENT CHEMICAL PATHWAY THAN $CYTK, ) SOTAGLIFLOZIN FROM $LXRX HELPS THE MUSCLE WALL ITSELF BECOME MORE FLEXIBLE AND DOES NOT SLOW DOWN THE HEART ITSELF = GOOD ) PHASE 3 RESULTS = GOOD. $NVO $VRTS $BIB
1 replies
macrossluvsrobotech Aug 28, 2:03 PM
$LXRX :What the Big Heart Trial News ACTUALLY Means (Plain English) Competitor Cytokinetics dropped Phase 3 data for stiff-heart disease (nHCM). Here is the layman breakdown: 1. KCCQ (+3.0 pts): A 0-100 symptom questionnaire. A 3-pt gain is barely noticeable to patients. 2. Peak VO2 (+0.67): Oxygen used during max exercise. +0.67 is just a few extra seconds on a treadmill. 3. LVEF <50% (10.5% vs 0.8%): Ejection Fraction is heart pump strength (normal = 50-70%). 10.5% of patients had their heart pump dangerously weakened into heart failure territory! The Takeaway for Lexicon ($LXRX): The competing class works by putting a "speed limiter" on the heart motor, but it risks stalling the pump. Lexicon’s drug (sotagliflozin in Phase 3 SONATA-HCM) works differently: it improves cellular energy and reduces stiffening WITHOUT weakening the heart pump. This safety scare blows the door wide open for $LXRX. Full SEC & Trial Data: https://investors.lexpharma.com $CYTK $NVO $BIB $VRTS
0 replies